Horizon Technology Finance: BioVaxys Acquires DPX™ Technology for Advanced Immunotherapy Development

BioVaxys Advances Immunotherapy with Strategic Acquisition of DPX™ Technology

BioVaxys Technology Corp. has solidified its position in the biopharmaceutical landscape through the recent acquisition of the assets and intellectual property of the former IMV Inc., focusing on the DPX™ immune-educating platform technology. This acquisition, formalized via an Asset Purchase Agreement (APA) dated February 11, 2024, signifies a pivotal moment for BioVaxys, which is dedicated to developing advanced immunotherapies. The DPX™ technology offers a unique method for instructing the immune system to create tailored responses against various medical conditions, including cancers and immunological disorders.

Initially, BioVaxys faces the challenge of raising USD $10 million by December 31, 2024, as stipulated in the APA. However, due to subsequent amendments, this deadline has been extended to June 30, 2025, providing the company with additional time to secure the necessary funding. More significantly, the performance milestone has undergone substantial reductions, now set at USD $1,785,625 by an amendment on September 25, 2025. If BioVaxys successfully meets this revised target by September 30, 2026, the relevant section of the APA will become inactive, allowing the company to focus its resources on research and development rather than financial obligations.

The acquisition aligns with BioVaxys's commitment to advancing its clinical pipeline, which includes the promising drug maveropepimut-S (MVP-S), currently in Phase IIB development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer. By leveraging the DPX™ platform, BioVaxys aims to create innovative therapies that utilize survivin-derived antigenic peptides to elicit potent immune responses. This strategic move not only enhances the company's portfolio but also holds the potential to improve patient care through novel treatment options.

In addition to the acquisition, BioVaxys remains focused on ongoing developments within its immunotherapy pipeline. The company's dedication to addressing unmet medical needs through innovative solutions highlights its role in the evolving landscape of biopharmaceuticals. This commitment to advancing immunotherapies positions BioVaxys favorably in a competitive market, where the demand for effective cancer treatments continues to grow.

Moreover, the revised milestones set forth in the APA reflect BioVaxys’s proactive approach to financial management amid its ambitious growth strategy. By reducing the initial funding requirements, the company demonstrates an understanding of market dynamics and the importance of maintaining momentum in research and development while securing necessary capital for future innovations.